Summary.-Animals bearing metastatic fibrosarcomas were treated with cyclophosphamide (CY) alone or in combination with flurbiprofen (FP), an inhibitor of prostaglandin synthesis. FP did not affect local growth of fibrosarcomas, and the incidence of distant metastases after resection of the "primary" implants was comparable in treated and control groups. Treatment with CY retarded growth of the fibrosarcomas and reduced the proportion of animals which succumbed to metastases, but this was not altered significantly by additional treatment with FP. FP did not affect the survival of rats bearing a lymphoid leukaemia. The lifespan of animals treated with CY was increased significantly, but the concomitant administration of FP did not enhance this effect.
. This led to the idea that prostaglandins might influence tumour growth and dissemination (Jaffe, 1974; Plescia et al., 1975; Bennett et al., 1975; Dowsett et al., 1976; Atkins et al., 1977) . Although the manner in which this may be achieved is not clear, it has been proposed that increased prostaglandin production by tumours may subvert the immune response of the host, or may aid bone destruction or tissue breakdown, thereby facilitating neoplastic invasion. Recently, it has been reported that concomitant treatment with inhibitors of prostaglandin synthesis improved the therapeutic effect of cytotoxic agents (Powles et al., 1978; Bennett et al., 1979; Berstock et al., 1980) . We have sttudied the effect of short-term administration of flurbiprofen (Froben, The Boots Company Ltd), a potent inhibitor of prostaglandin synthesis, alone or in combination with cyclophosphamide, on the growth and dissemination of 2 spontaneously metastatic rodent sarcomas and a lymphoid leukaemia of rats.
MATERIALS AND METHODS
Animnals.-Male (220-270g) and female (120-170g) Lister Hooded/Cbi rats and male (20-30g) C57BL/Cbi mice over 10 weeks of age were supplied by the Chester Beatty Research Institute animal-breeding colony.
Rat tumours.-MC28, a methylcholanthrene-induced fibrosarcoma, was maintained in syngeneic recipients by i.m. injection of a mechanically prepared brei of tumour tissue.
Single-cell suspensions were prepared by trypsinisation of the tumour. About 106 viable cells (as assessed by Trypan blue exclusion) were injected s.c. into the flank for the growth studies. This tumour is weakly immunogenic and has a high incidence of spontaneous metastases.
The lymphoid leukaemia HRL was of spontaneous origin. Iv. injection of 106 cells kills syngeneic rats with widespread disease within 3 weeks.
Mouse tumours.-FS6MI, a benzo(a)pyreneinduced fibrosarcoma was maintained by serial i.m. passage in syngeneic C57BL/CBi mice. It is weakly immunogenic, with a high metastatic incidence (Mantovani, 1978) .
Drugs.-Flurbiprofen (Froben, The Boots Company Ltd, FP) is a potent non-steroidal anti-inflammatory drug (NSAID) which inhibits the formation of prostaglandins from precursor fatty acids. Animals were treated thrice daily for 3 days at specified times during tumour growth (Powles et at., 1978) . FP was administered s.c. in saline at doses of 7 mg/kg in rats and 5 mg/kg in mice.
Cyclophosphamide (Endoxana, CY) was administered as a single i.p. injection of 10 or 100 mg/kg to mice and 80 mg/kg to rats, on the second day of FP treatment (Powles et al., 1978) . survival data were analysed using KaplanMeier lifetables and logrank P values as defined by Peto et al. (1976) and their significance assessed using x2 tests; a P of <0 05 was considered significant.
RESULTS

Effects offlurbiprofen and cyclophosphamide
Primary tumour growth.- Fig. 1 shows that FP, given for 3 days, did not affect the primary growth of rat sarcoma MC28; the development of tumours in groups of animals treated with 80 mg/kg CY was delayed by 10 days, but this was not changed significantly by the concomitant administration of FP. Similarly, the FS6M1 tumours of mice which had received 10 mg/kg CY alone, or in combination with FP, were of similar size (P> 0.05) (Fig. 2) ; 100 mg/kg CY delayed tumour growth (P < 0 01) but this was not affected by additional treatment with FP (P > 0-05).
Rats with the HRL leukaemia given CY alone or in combination with FP survived significantly longer (P < 0-001) than controls or those receiving FP alone (Fig. 3) . However, animals receiving both CY and FP became moribund at the same time as those receiving CY alone (Fig. 3 ). by concomitant FP. The survival curves shown in Fig. 5 lead to a similar conclusion.
Mice which had borne the FS6M1 fibrosarcoma and had received control injections of saline died of pulmonary and lymphatic metastases within 50 days of tumour resection. This proportion was not altered significantly by 10 mg/kg CY alone or in combination with FP (P = 0047). The proportion of animals with pulmonary or lymphatic metastases following treatment with 100 mg/kg CY was significantly lower (P < 001) than the proportion in groups receiving saline or 10 mg/kg CY (Table) . Kidney and liver metastases occurred in a few animals, but their low incidence (Table) did not allow a valid statistical appraisal. The probability of survival was significantly greater (P < 0.05) in animals treated with 100 mg/kg CY (± FP) than those which had received 10 mg/kg CY ( ± FP) or saline (Table and Fig . 6 ). The survival of FP-treated mice was slightly greater than controls (P = 0 057) and although FP tended to improve the probability of survival for mice treated with 10 mg/kg (P= 0.08) or 100 mg/kg (P = 0.38) CY, this
was not significant at the 5% level.
DISCUSSION
The experiments reported above were undertaken to investigate the effect of a treatment combining the cytotoxic agent cyclophosphamide (CY), and flurbiprofen (FP), an inhibitor of prostaglandin synthesis, on the growth and dissemination of 3 rodent tumours. Previous reports in the literature had indicated that FP enhanced the therapeutic effect of an alkylating agent against an ascitic rat tumour (Powles et al., 1978) and of radiation and cytotoxic agents against the local growth and secondary spread of a murine adenocarcinoma Berstock et al., 1980) .
The HRL rat leukaemia used in our study disseminates via the blood stream, and animals succumb to widespread disease within 3 weeks. The progression of this tumour was not affected by treatment with FP for 3 days. The increased animal survival time with CY was not significantly affected by the concomitant administration of FP.
The fibrosarcomas chosen for this study disseminate spontaneously via both lymphatic and haematogenous routes, and the very low incidence of locally recurrent tumours (< 50) allowed a clear assessment of the effect of a particular treatment on distant metastases (any animal with a local regrowth of tumour at the excision site was not included in the statistical analysis). In summary, short-term treatment with FP alone did not affect primary growth of the fibrosarcomas; the incidence of distant metastases following resection of the tumours was also comparable to that in untreated controls, though the probability of survival was slightly greater for groups of mice receiving FP (P = 0 057). Treatment of mice with FS6M1 fibrosarcoma with 10mg/kg CY did not improve the probability of survival (P> 0.05) . High doses of CY retarded growth of the fibrosarcomas and reduced the proportion of animals which succumbed to metastases (P < 0 05) and although additional treatment with FP tended to increase the probability of survival in mice (P = 0-08 for 10 mg/kg CY and P=0 38 for 100 mg/kg CY this was not significant at the 5% level.
Experiments in which anti-inflammatory drugs (NSAID) alone have been administered to tumour-bearing animals have yielded disparate results: some authors have recorded that such treatment did not affect tumour growth (Sykes & Maddox, 1972; Powles et al., 1978) whilst others have found it inhibited (Tashjian et al., 1973; Plescia et al., 1975; Hial et al., 1976) and animal survival increased (Strausser & Humes, 1975; Lynch et al., 1978) particularly if treatment with the NSAID was initiated at the same time as tumour inoculation Trevisani et al., 1980) . As FP was administered for only a short period during tumour growth in this study, further experiments were performed in which FP treatment was initiated the day of tumour inoculation and continued daily until resection; this protocol also failed to affect the growth and dissemination of the sarcomas, as reported elsewhere (Heckford, 1980) . FP has been shown to inhibit prostaglandin formation at doses of 0 1-0 5 mg/ kg (Whittle et al., 1980) but over 3 days, the high doses used in this study (5-7 mg/ kg) were well tolerated, with no evidence of gastro-intestinal toxicity.
The results described above demonstrate that, for small groups of animals, shortterm treatment with FP exerted a small but statistically insignificant enhancement of the therapeutic effect of CY against the primary and secondary growth of 3 rodent tumours. Reports of other experiments, using different treatment protocols and tumours of various histogenic origin, have yielded some evidence of enhancement of the therapeutic effect of cytotoxic drugs by concomitant administration of NSAIDs. Further experiments must be undertaken, in order to identify any effects of anti-inflammatory drugs on tumour growth and dissemination. 
